Wednesday, July 8, 2026

pharma · Knee Osteoarthritis · Hypoplastic Left Heart Syndrome · RGBP

Regeneron Ireland Designated

Regeneron Ireland Designated is a pharma organization headquartered in LA MESA, CA, IE. It trades on NYSE under ticker RGBP. Primary therapeutic focus areas include Knee Osteoarthritis, Hypoplastic Left Heart Syndrome, C

LA MESA, CA, IE HQ
Public company Type
RGBP · NYSE Ticker
Company details
Status
Public
HQ
LA MESA, CA, IE
Programs
10
Drugs
62
Patents
8292
Clinical program

hyaluronic Acid + platelet-rich plasma

Approved · small molecule · Knee Osteoarthritis

hyaluronic Acid + platelet-rich plasma for Knee Osteoarthritis is a Approved program (small_molecule) at Regeneron Ireland Designated Activity Company (DAC) with 1 ClinicalTrials.gov record(s).

Internal code ACP-HA

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Regeneron Ireland Designated Activity Company (DAC)
Phase
Approved
Modality
small_molecule
Indication
Knee Osteoarthritis
Status
completed
Trials
1

Clinical trials